Aligos Therapeutics Inc (ALGS)

13.04 -0.66  -4.82% NASDAQ Dec 3, 16:00 13.00 -0.04  -0.31% After-Hours: 20:00 USD

Aligos Therapeutics Shareholders Equity (Quarterly):

217.01M for Sept. 30, 2021
View 4,000+ financial data types
Browse...
View Full Chart

Shareholders Equity (Quarterly) Chart

Export Data
Save Image
Print Image

Historical Shareholders Equity (Quarterly) Data

View and export this data going back to 2019. Start your Free Trial
Export Data Date Range:
Data for this Date Range  
Sept. 30, 2021 217.01M
June 30, 2021 168.88M
March 31, 2021 195.22M
Dec. 31, 2020 220.04M
   
Sept. 30, 2020 -136.67M
June 30, 2020 121.96M
Dec. 31, 2019 -64.89M

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.

Advertisement

Shareholders' Equity Definition

Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.

Read full definition.

Shareholders Equity (Quarterly) Benchmarks

CEL-SCI Corp 59.79M
AIM ImmunoTech Inc 62.05M
NovaBay Pharmaceuticals Inc 9.364M

Shareholders Equity (Quarterly) Range, Past 5 Years

Minimum -136.67M Sep 2020
Maximum 220.04M Dec 2020
Average 103.08M

Shareholders Equity (Quarterly) Related Metrics

Total Assets (Quarterly) 263.07M
Total Liabilities (Quarterly) 46.06M
Current Ratio 7.150

News

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.